carbon tetrachloride has been researched along with incb-018424 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashamallah, SA; Hazem, SH; Ibrahim, TM; Shaker, ME | 1 |
| Dai, G; Hong, J; Li, A; Liu, X; Liu, Y; Luo, Y; Song, Z; Xiao, H; Zhang, W | 1 |
2 other study(ies) available for carbon tetrachloride and incb-018424
| Article | Year |
|---|---|
The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms.
Topics: Animals; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Janus Kinases; Liver; Male; Mice; Mice, Inbred BALB C; Nitriles; Oxidative Stress; Peroxidase; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors | 2014 |
Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; Fibrosis; Hepatic Stellate Cells; Humans; Janus Kinase 1; Janus Kinase 2; Liver; Liver Cirrhosis; Liver Neoplasms; Mice; Nitriles; Pyrazoles; Pyrimidines | 2022 |